Alpha 2.0
Login Register
» Authors » Anna-Maria Hoffmann-Vold

Anna-Maria Hoffmann-Vold

Explore the profile of Anna-Maria Hoffmann-Vold including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 118
Citations 2106
Followers 0
Related Specialties
Rheumatology
Pulmonary Medicine
General Medicine
Top 10 Co-Authors
Oliver Distler
Oyvind Molberg
Oyvind Midtvedt
Yannick Allanore
Vanessa Smith
Torhild Garen
Havard Fretheim
Armando Gabrielli
Paolo Airo
Cathrine Brunborg
Published In
Rheumatology (Oxford)
Lancet Rheumatol
RMD Open
Ann Rheum Dis
Arthritis Rheumatol
Affiliations
Soon will be listed here.
Recent Articles
1.
Validation of a semi-quantitative method to assess interstitial lung disease severity and progression in systemic sclerosis by standard and low-dose HRCT scans
Tschaler L, Jordan S, Aalokken T, Becker M, Brunborg C, Bruni C, et al.
RMD Open . 2025 Feb; 11(1). PMID: 40021203
Background: While the presence of distinct imaging abnormalities by high-resolution CT (HRCT) defines interstitial lung disease (ILD), there is a relative lack of validated methods to quantify these abnormalities in...
2.
Evaluation of Systemic Sclerosis Primary Heart Involvement and Chronic Heart Failure in the European Scleroderma Trials and Research Cohort
Gyorfi A, Filla T, Polzin A, Tascilar K, Buch M, Trobs M, et al.
J Am Heart Assoc . 2025 Feb; 14(5):e036730. PMID: 40008525
Background: Systemic sclerosis (SSc) primary heart involvement (SSc-pHI) is one of the leading causes of mortality in SSc. We aimed to evaluate risk factors for SSc-pHI and its progression and...
3.
How to build a framework to establish a patient research partner network in rheumatology research: a report of a 2-year implementation project
Buerki K, Toitou M, de Wit M, Grealis S, Ludwig S, Britt C, et al.
RMD Open . 2025 Feb; 11(1). PMID: 39929597
Background: Patient research partners (PRPs) are people living with a relevant disease who actively contribute to research. Their contribution is beneficial for any research project. Although the inclusion of PRPs...
4.
Faecal microbiota transplantation in patients with systemic sclerosis and lower gastrointestinal tract symptoms in Norway (ReSScue): a phase 2, randomised, double-blind, placebo-controlled trial
Fretheim H, Barua I, Bakland G, Dhainaut A, Halse A, Carstens M, et al.
Lancet Rheumatol . 2025 Feb; PMID: 39900089
Background: Gastrointestinal tract involvement is highly prevalent in systemic sclerosis, with few treatment options. We assessed the efficacy and safety of faecal microbiota transplantation using standardised anaerobic cultivated human intestinal...
5.
Post hoc comparison of the effectiveness of tocilizumab, rituximab, mycophenolate mofetil, and cyclophosphamide in patients with SSc-ILD from the EUSTAR database
Yan Q, Bruni C, Garaiman A, Mihai C, Jordan S, Becker M, et al.
Ann Rheum Dis . 2025 Feb; PMID: 39894689
Objectives: Tocilizumab (TCZ), rituximab (RTX), mycophenolate mofetil (MMF), and cyclophosphamide (CYC) are the immunosuppressants (IS) most frequently used for systemic sclerosis-associated interstitial lung disease (SSc-ILD). This post hoc study aimed...
6.
A comparative analysis of risk stratification tools in systemic sclerosis-associated pulmonary arterial hypertension: a EUSTAR analysis
Bjorkekjaer H, Bruni C, Broch K, Brunborg C, Carreira P, Airo P, et al.
Rheumatology (Oxford) . 2025 Jan; PMID: 39878955
Objectives: The 2022 European Society of Cardiology and European Respiratory Society (ESC/ERS) Guidelines for pulmonary arterial hypertension (PAH) recommend risk stratification to optimize management. However, the performance of generic PAH...
7.
EULAR recommendations for the treatment of systemic sclerosis: 2023 update
Del Galdo F, Lescoat A, Conaghan P, Bertoldo E, colic J, Santiago T, et al.
Ann Rheum Dis . 2025 Jan; 84(1):29-40. PMID: 39874231
Objectives: To update the 2017 European Alliance of Associations for Rheumatology (EULAR) recommendations for treatment of systemic sclerosis (SSc), incorporating new evidence and therapies. Methods: An international task force was...
8.
Gastroesophageal reflux disease is associated with a more severe interstitial lung disease in systemic sclerosis in the EUSTAR cohort
Roth E, Bruni C, Petelytska L, Becker M, Dobrota R, Jordan S, et al.
Rheumatology (Oxford) . 2025 Jan; PMID: 39775478
Objectives: Gastroesophageal reflux disease (GERD) is frequent in systemic sclerosis (SSc) and could predict progression of interstitial lung disease (ILD). We aimed to analyse (1) the prevalence of GERD among...
9.
Rationale for phosphodiesterase-4 inhibition as a treatment strategy for interstitial lung diseases associated with rheumatic diseases
Aringer M, Distler O, Hoffmann-Vold A, Kuwana M, Prosch H, Volkmann E
RMD Open . 2024 Dec; 10(4). PMID: 39719300
Interstitial lung disease (ILD) associated with rheumatoid arthritis or with connective tissue diseases such as systemic sclerosis can be collectively named systemic autoimmune rheumatic disease-associated ILDs (SARD-ILDs) or rheumatic musculoskeletal...
10.
A Phase II study of avenciguat, a novel soluble guanylate cyclase activator, in patients with systemic sclerosis: Study design and rationale of the VITALISScE™ study
Khanna D, de Vries-Bouwstra J, Hoffmann-Vold A, Kuwana M, Low A, Proudman S, et al.
J Scleroderma Relat Disord . 2024 Nov; :23971983241291923. PMID: 39544899
Introduction: Systemic sclerosis is a rare autoimmune connective tissue disease characterised by (1) microvasculopathy; (2) immune dysregulation; and (3) progressive fibrosis of the skin and internal organs. Soluble guanylate cyclase...